EU and US could reach trade deal this weekend - Reuters
Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, has reached an all-time high, with its stock price soaring to $179.37. The company’s strong market position is reflected in its $19.94 billion market capitalization and impressive year-to-date return of 19.23%. According to InvestingPro analysis, the stock currently appears slightly overvalued relative to its Fair Value. This milestone reflects a significant uptrend in the company’s market performance, marking a remarkable 1-year change with an increase of 25.07%. Investors have shown increased confidence in Quest Diagnostics, as the company continues to expand its services and leverage technological advancements to enhance patient care and streamline diagnostics. The company’s stability is evidenced by its 13-year streak of dividend increases and consistently low price volatility. InvestingPro data reveals that 9 analysts have revised their earnings upward for the upcoming period, suggesting continued positive momentum. The all-time high represents a culmination of strategic growth initiatives and a robust demand for diagnostic testing, which has been a critical component in healthcare, especially in the wake of the global health landscape.
In other recent news, Quest Diagnostics reported its Q1 2025 earnings, surpassing market expectations with an adjusted earnings per share (EPS) of $2.21, compared to a forecasted $2.16. Revenue reached $2.65 billion, slightly above the anticipated $2.64 billion, marking a year-over-year growth of 12.1%. Fitch Ratings upgraded Quest Diagnostics’ Long-Term Issuer Default Rating to ’BBB+’ with a stable outlook, acknowledging the company’s strong operational performance and steady demand for clinical testing. JPMorgan revised its price target for Quest Diagnostics to $190, maintaining a Neutral rating, following the company’s robust quarterly performance. Analysts from JPMorgan project adjusted EPS of $9.70 for 2025 and $10.53 for 2026, reflecting confidence in the laboratory services’ stability. Quest Diagnostics also reaffirmed its full-year 2025 revenue guidance of $10.7 to $10.85 billion and adjusted EPS guidance of $9.55 to $9.80. The company continues to focus on strategic initiatives, including mergers and acquisitions, with an expected allocation of $2 billion towards M&A activities from 2025 to 2028. Additionally, Quest Diagnostics launched innovative diagnostic tests, such as the AD DETECT blood test for Alzheimer’s, contributing to its growth in advanced diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.